45 related articles for article (PubMed ID: 2547349)
1. Cardiovascular action of penta-O-ethylquercetin in the rat.
Cheav SL; Prigent AF; Picq M; Foussard-Blanpin O; Pacheco H
Arch Int Pharmacodyn Ther; 1989; 298():108-24. PubMed ID: 2547349
[TBL] [Abstract][Full Text] [Related]
2. Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
Picq M; Prigent AF; Némoz G; André AC; Pacheco H
J Med Chem; 1982 Oct; 25(10):1192-8. PubMed ID: 6292419
[TBL] [Abstract][Full Text] [Related]
3. Effect of two flavonoid compounds on central nervous system. Analgesic activity.
Picq M; Cheav SL; Prigent AF
Life Sci; 1991; 49(26):1979-88. PubMed ID: 1660953
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the different cyclic nucleotide phosphodiesterase isoforms separated from rat brain by flavonoid compounds.
Picq M; Dubois M; Prigent AF; Némoz G; Pacheco H
Biochem Int; 1989 Jan; 18(1):47-57. PubMed ID: 2541724
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride.
Sellin LC; Alajoutsijärvi A; Törnquist K; Fraser M; Pippuri A; Ojala I
Arzneimittelforschung; 1988 Dec; 38(12):1787-9. PubMed ID: 2854467
[TBL] [Abstract][Full Text] [Related]
6. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Jackson EK
J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
[TBL] [Abstract][Full Text] [Related]
8. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of some flavonoids and falvonoid mixtures on cyclic AMP phosphodiesterase activity of rat heart.
Petkov E; Nikolov N; Uzunov P
Planta Med; 1981 Oct; 43(2):183-6. PubMed ID: 6273955
[No Abstract] [Full Text] [Related]
10. Microdialysis of noradrenaline in rostral ventrolateral medulla after intravenous methionine enkephalin administration in anesthetized rats.
Rhee HM; Strickland JA; Mason PA
Can J Cardiol; 1992 Jun; 8(5):527-35. PubMed ID: 1617531
[TBL] [Abstract][Full Text] [Related]
11. [Action of glycerolformal on the cardiovascular system].
Cheav SL; Salloum S; Pieri F; Kirkiacharian S
Ann Pharm Fr; 1985; 43(5):491-503. PubMed ID: 3835839
[No Abstract] [Full Text] [Related]
12. Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat.
Sirén AL; Feuerstein G
J Pharmacol Exp Ther; 1988 Oct; 247(1):69-78. PubMed ID: 2459371
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
14. Peripheral and central cardiovascular effects of ketanserin in conscious normotensive rats.
Davy M; Midol-Monnet M; Heimburger M; Beslot F; Cohen Y
Arch Int Pharmacodyn Ther; 1987 Dec; 290(2):193-206. PubMed ID: 3128194
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of inodilatory responses by non-invasive measures of cardiovascular performance in healthy man.
De Mey C; Erb K; Schroeter V; Belz GG
Int J Clin Pharmacol Ther; 1996 Dec; 34(12):525-32. PubMed ID: 8996846
[TBL] [Abstract][Full Text] [Related]
16. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
Clark BJ; Bucher T; Waite R
J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
Nagata K; Ogawa T; Omosu M; Fujimoto K; Hayashi S
Arzneimittelforschung; 1985; 35(7):1034-6. PubMed ID: 2996562
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological activities of the main metabolite of flavoxate 3-methylflavone-8-carboxylic acid.
Cazzulani P; Pietra C; Abbiati GA; Ceserani R; Oliva D; Civelli M; Tajana A; Nardi D
Arzneimittelforschung; 1988 Mar; 38(3):379-82. PubMed ID: 2838033
[TBL] [Abstract][Full Text] [Related]
20. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
